More than 50 million Americans regularly engage with Newsmax, whether through its broadcasts or various publications. Following a recently announced expansion into Europe and the Middle East, the company anticipates a significant increase in its global audience. Forbes magazine has described Newsmax as a “news powerhouse.” However, despite this recognition, Newsmax’s stock performance has not mirrored its strong viewership. Aside from a brief surge after its initial public offering (IPO) in late March and early April, the company’s stock has faced challenges throughout the year.
Looking ahead, predictions suggest that the outlook for Newsmax may not be as promising as that for three other stocks expected to surpass it in value over the next five years.
Firstly, Fox Corp stands out as Newsmax’s most significant competitor in the conservative news landscape. Currently, Fox boasts a market capitalization close to $31 billion, dwarfing Newsmax’s market cap of approximately $1.1 billion. Even if market sizes were comparable, Fox’s strong revenue growth in its latest quarter suggests it will continue to outperform.
In the third quarter of 2025, Newsmax reported a net loss of $4.1 million, while Fox managed a profit of $690 million for the same period. This financial disparity highlights a critical difference between the two companies. Furthermore, Fox’s shares are trading at a more attractive price-to-sales ratio of 1.8, which is significantly lower than Newsmax’s forward sales multiple of 6.
Secondly, Mirum Pharmaceuticals emerges as a compelling contender for future growth. With a market cap of around $4 billion, Mirum is positioned for significant upward trajectory, especially compared to Newsmax. Mirum has reported revenue growth of 47% year-over-year driven by its liver disease drug, Livmarli, whose sales are burgeoning. The company anticipates that Livmarli could evolve into a blockbuster drug, bolstered by a robust pipeline of additional promising therapies. Notably, Mirum is in the process of acquiring Bluejay Therapeutics, which is developing a new treatment for chronic hepatitis delta virus.
Lastly, The Trade Desk offers a promising alternative within the advertising sector. As a leading advertising technology company, The Trade Desk provides tools for agencies to position ads across a multitude of online platforms and streaming services. With a market cap of $18.6 billion, The Trade Desk already has a significant advantage over Newsmax.
Despite recent stock volatility, The Trade Desk is expected to yield greater long-term returns than Newsmax due to its expansion into ad-supported connected TV and international markets. As the advertising landscape evolves, companies like The Trade Desk are well-positioned to capitalize on growth opportunities.
In summary, while Newsmax continues to grow its audience domestically and internationally, analysts predict that it will face stiff competition from Fox Corp, Mirum Pharmaceuticals, and The Trade Desk over the next five years. Each of these companies presents unique strengths that may well lead to superior financial performance compared to Newsmax.
